Bukwang Pharm. Co. (www.bukwang.co.kr), Ltd. is a leading Korean pharmaceutical company listed on the Korean Stock Exchange [KRX:003000]. The company has been in business for over 50 years, and achieved US$150 million in sales in 2020. Sales are primarily derived from products licensed from Europe, the United States, and Japan. The company is currently investing significant resources in R&D to create a robust pipeline of preclinical and clinical agents for the treatment of antiviral diseases, gastrointestinal disorders, CNS disorders and metabolic disease. Bukwang is our partner for JM-010.
Medici Investment is one of the most prestigious VCs and PEs in Korea. They have invested in many companies within various areas; especially, Medici is recognized for investments in biotech companies, ever since their inception in 2011. In addition, Medici is well known VC as an outstanding GP of many blind funds built and managed in Korea. Medici´s total invested assets are around USD 1.1B and it has recorded the best financial profit rate among all venture capitals in Korea.